Lucid Diagnostics grants director 123,000 shares

SOKOLOV JACQUE J reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 02/24/2026 - 06:48 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

SOKOLOV JACQUE J reported acquisition or exercise transactions in this Form 4 filing.

Lucid Diagnostics Inc. director Jacque J. Sokolov reported an equity award of 123,000 shares of Common Stock. The shares are restricted stock granted under the company’s 2018 Equity Plan and carry a single vesting date of May 20, 2029, subject to forfeiture if the required service is not completed.

After this grant, Sokolov directly holds 320,460 shares of Lucid Diagnostics common stock.

Insider Trade Summary

Grant/Award: 123,000 shares

Grant/Award 1 txn

Insider SOKOLOV JACQUE J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	123,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 320,460 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lucid Diagnostics (LUCD) report for Jacque J. Sokolov?

Lucid Diagnostics reported that director Jacque J. Sokolov received a grant of 123,000 shares of restricted Common Stock. The award was made under the company’s 2018 Equity Plan and is recorded as a grant, award, or other acquisition transaction, not an open-market purchase or sale.

When do Jacque J. Sokolov’s 123,000 Lucid Diagnostics (LUCD) restricted shares vest?

The 123,000 restricted shares granted to Jacque J. Sokolov have a single vesting date of May 20, 2029. Vesting depends on completion of the requisite service period; if that service requirement is not met, the restricted stock is subject to forfeiture under the grant terms.

How many Lucid Diagnostics (LUCD) shares does Jacque J. Sokolov hold after this Form 4 transaction?

Following the reported grant, Jacque J. Sokolov directly holds 320,460 shares of Lucid Diagnostics Common Stock. This total includes the newly awarded 123,000 restricted shares reported in the Form 4, which remain subject to vesting conditions tied to continued service with the company.

What type of insider transaction is shown in Lucid Diagnostics (LUCD) Form 4 for Jacque J. Sokolov?

The Form 4 shows a transaction coded “A,” which is classified as a grant, award, or other acquisition of non-derivative Common Stock. It reflects an equity award under the 2018 Equity Plan rather than a market purchase or sale, with 123,000 restricted shares granted to the director.

Under which equity plan were Jacque J. Sokolov’s Lucid Diagnostics (LUCD) shares granted?

The 123,000 restricted shares reported for Jacque J. Sokolov were granted under Lucid Diagnostics’ 2018 Equity Plan. This plan allows the company to issue equity-based awards, and the reported grant is one such restricted stock award, subject to vesting and potential forfeiture conditions described in the filing.

Are Jacque J. Sokolov’s new Lucid Diagnostics (LUCD) shares subject to forfeiture?

Yes. The filing states the 123,000 restricted shares granted to Jacque J. Sokolov are subject to forfeiture if the requisite service period is not completed. The shares have a single vesting date of May 20, 2029, and continued service through that date is required.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SOKOLOV JACQUE J

(Last) (First) (Middle)

360 MADISON AVENUE

25TH FLOOR

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lucid Diagnostics Inc. [ LUCD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		A		123,000(1)	A	$0	320,460	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed

	/s/ Michael A. Gordon, by power of attorney	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.